HoldsUp

David Perlmutter

David Perlmutter is a neurologist and author focusing on cognitive health and neurodegenerative disorders. His published research investigates Alzheimer's disease prevention, intracerebral fructose and uric acid metabolism, and brain inflammation. His work also covers clinical evaluations of treatments for Parkinson's disease, gluten sensitivity, and statin use.

66 claims checked on air: 9 context 2 contradicted 5 overstated 47 supported 3 unverified

What they said on air

0:00:00supportedmoderateWhy 1 in 2 Seniors Get Alzheimer's (And How to Be the Except

Between 40% and 50% of adults in the United States who live to age 85 will receive a diagnosis of Alzheimer's disease.

"When we recognize that 40 to 50% of adults in America who live to be age 85 will have a diagnosis of Alzheimer's disease" (said at 0:00:00)

Landmark US epidemiological studies, such as the East Boston community-based study by Evans and colleagues (JAMA 1989), found that 47.2% (95% CI: 37.0%–63.2%) of adults aged 85 years and older had clinically diagnosed probable Alzheimer's disease. While some newer population models estimate the point prevalence among adults aged 85 and older to be slightly lower (approximately 32% to 38%), the 40% to 50% estimate is well-established in the landmark literature for this age demographic in the United States.

0:00:15supportedmoderateWhy 1 in 2 Seniors Get Alzheimer's (And How to Be the Except

Among people aged 65 and older, 1 in 9 (or 11%) have dementia.

"at 65 years and older, risk is 1 in 9 or 11% of people age 65 or older have dementia." (said at 0:00:15)

The speaker's claim accurately reflects widely reported epidemiological statistics from the Alzheimer's Association (published in its annual Facts and Figures reports). Approximately 10.7% to 11% (or about 1 in 9) of Americans aged 65 and older have Alzheimer's dementia (an estimated 6.5 million individuals in 2022 out of roughly 58 million older adults).

0:02:34supportedmoderateWhy 1 in 2 Seniors Get Alzheimer's (And How to Be the Except

Microglial cells in their supportive state maintain synapses, neuronal function, and the blood-brain barrier.

"They maintain our synapses. They maintain the function of the neurons. They maintain the blood-brain barrier." (said at 0:02:34)

Published neurobiological literature supports the claim that homeostatic (supportive/resting) microglia play active physiological roles in CNS maintenance. In physiological conditions, microglia preserve neural circuit integrity by sculpting and pruning synapses, supporting neuronal survival and function, and participating in the neurovascular unit to help regulate and maintain blood-brain barrier integrity.

0:03:36supportedlowWhy 1 in 2 Seniors Get Alzheimer's (And How to Be the Except

M1-activated microglia destroy synapses, generate neuroinflammation, impair neuronal function, and increase the permeability of the blood-brain barrier.

"they can shift to being destructive, what I call in the book the "evil twin," the M1 configuration, where they are going around and destroying the synapses, creating that neuroinflammatory environment where the neurons can't work well anymore and the blood-brain barrier becomes more permeable" (said at 0:03:36)

The speaker's statement accurately summarizes the classical neuroimmunological model of M1 microglial activation. Pro-inflammatory (M1) microglia release pro-inflammatory cytokines, chemokines, and reactive oxygen species that generate a neuroinflammatory environment, promote aberrant synaptic pruning/loss, impair neuronal and synaptic function, and compromise blood-brain barrier (BBB) integrity (increasing permeability). Evidence for these specific mechanisms is largely derived from preclinical in vitro and animal disease models.

0:04:26supportedvery lowWhy 1 in 2 Seniors Get Alzheimer's (And How to Be the Except

A higher-carbohydrate diet is associated with activation of microglial cells in the brain.

"why a higher-carb diet—and we'll unpack this today—is associated with activation of these microglial cells." (said at 0:04:26)

Preclinical evidence supports the association between high-carbohydrate (particularly refined carbohydrate and high-fructose) diets and microglial activation in the central nervous system. In rodent models, chronic consumption of high-carbohydrate or high-fructose diets consistently increases markers of microglial activation (such as IBA-1 and CD11b) and triggers neuroinflammatory cytokine signaling across brain regions such as the hippocampus and prefrontal cortex. Because this evidence is derived almost entirely from animal and mechanistic models rather than direct human neuroimaging or histological studies, the GRADE certainty is very low.

0:04:37supportedmoderateWhy 1 in 2 Seniors Get Alzheimer's (And How to Be the Except

Changes in gut bacteria leading to intestinal permeability cause increased systemic inflammation that activates microglial cells.

"permeability of the gut, of all things, from having changes in our gut bacteria leads to increased inflammation that will activate these microglial cells and shift them to becoming, again, the evil twin." (said at 0:04:37)

The described mechanistic cascade—where alterations in gut microbiota (dysbiosis) compromise the intestinal epithelial barrier, permitting the translocation of bacterial components like lipopolysaccharides into the bloodstream to trigger systemic inflammation and cross or signal across the blood-brain barrier to activate microglial cells—is well-documented in preclinical models and human experimental endotoxemia studies.

0:04:49needs contextmoderateWhy 1 in 2 Seniors Get Alzheimer's (And How to Be the Except

TSPO PET imaging can detect activated microglia in living humans.

"We now see that we can, research-wise anyway, image the brain in living humans using what's called a TSPO scan. This scan images when the microglia are activated to their destructive state." (said at 0:04:49)

TSPO (18 kDa translocator protein) PET imaging is widely used in living human research to visualize neuroinflammation and microglial activation in vivo. However, the claim requires two important qualifications: first, TSPO is not exclusive to microglia, as it is also expressed by reactive astrocytes and constitutively by vascular endothelial cells; second, elevated TSPO signal reflects overall cellular upregulation/density and does not specifically distinguish a purely 'destructive' phenotype from other states of microglial activation or repair.

0:05:09overstatedmoderateWhy 1 in 2 Seniors Get Alzheimer's (And How to Be the Except

Positive TSPO scans showing microglial activation are observed in Alzheimer's disease, Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, major depressive disorder, PTSD, and long COVID.

"we see that the TSPO scan is positive, as you would expect, in Alzheimer's, in Parkinson's, in multiple system atrophy, progressive supranuclear palsy, major depressive disorder, post-traumatic stress, and even long COVID." (said at 0:05:09)

While translocator protein (TSPO) PET imaging reliably shows increased radiotracer uptake (reflecting glial activation/neuroinflammation) in neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, multiple system atrophy (MSA), and progressive supranuclear palsy (PSP), as well as in corticolimbic circuits in major depressive disorder, the claim is overstated for PTSD and long COVID. In long COVID, case-control TSPO PET studies have found that TSPO availability is not significantly elevated compared to healthy controls. In PTSD, in vivo TSPO PET imaging studies frequently report decreased TSPO binding (neuroimmune suppression) rather than increased TSPO signals.

0:12:24overstatedmoderateWhy 1 in 2 Seniors Get Alzheimer's (And How to Be the Except

Having type 2 diabetes increases the risk of developing Parkinson's disease by 85%.

"If you have type 2 diabetes, your risk of Parkinson's is increased by 85%." (said at 0:12:24)

Type 2 diabetes is associated with an increased risk of Parkinson's disease, but large meta-analyses show the relative risk increase is substantially lower than 85%. Comprehensive meta-analyses of prospective cohort studies consistently estimate an increased risk of roughly 15% to 37% (e.g., summary RR = 1.27, 95% CI 1.20–1.35 in a meta-analysis of 15 cohort studies encompassing nearly 30 million participants; RR = 1.22, 95% CI 1.08–1.37 in a 25-study meta-analysis). Claiming an 85% increase significantly overstates the effect size observed in the epidemiologic literature.

0:17:04supportedmoderateWhy 1 in 2 Seniors Get Alzheimer's (And How to Be the Except

The blood-brain barrier naturally becomes less functional and increasingly permeable as humans age.

"through the blood-brain barrier that becomes less and less functional as we age." (said at 0:17:04)

Observational neuroimaging studies (using dynamic contrast-enhanced MRI and multi-echo arterial spin labeling) and biomarker literature in humans show that blood-brain barrier (BBB) permeability increases and barrier function progressively declines as a normal feature of aging across several brain regions, an effect that is further exacerbated in age-related cognitive decline and neurodegenerative disease.

0:18:24supportedvery lowWhy 1 in 2 Seniors Get Alzheimer's (And How to Be the Except

In the 1980s, Dr. Langston showed that patients who used a contaminated designer IV drug experienced immediate microglial activation that destroyed dopamine-producing substantia nigra neurons, causing Parkinson's symptoms that showed ongoing microglial activity 13 to 14 years later.

"It's the same mechanism that was demonstrated by Dr. Langston in the 1980s when he first saw these patients who used a designer IV drug that was contaminated. The microglia were activated in their brains immediately and destroyed those cells that made the dopamine, and immediately they got Parkinson's. And he studied their brains 13, 14 years later, and these microglia were still at it, still destroying tissue." (said at 0:18:24)

The claim accurately describes the findings of Dr. J. William Langston and colleagues. In the early 1980s, Langston identified patients who developed acute parkinsonism after injecting synthetic heroin contaminated with MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine). In a 1999 post-mortem study of three of these patients who survived between 3 and 16 years (average roughly 13-14 years), Langston's team demonstrated ongoing nigrostriatal neurodegeneration accompanied by persistent microglial activation and clustering around substantia nigra neurons long after the initial exposure. Note that the evidence certainty is graded as very low because the human finding is based on a small post-mortem case series of three individuals.

0:19:22contradictedhighWhy 1 in 2 Seniors Get Alzheimer's (And How to Be the Except

Accumulation of beta-amyloid in the brain is not the cause of Alzheimer's disease.

"That is absolutely not the cause of Alzheimer's disease. I say that in the book, provide the data, explain how the whole amyloid hypothesis was flawed." (said at 0:19:22)

The speaker's categorical assertion that beta-amyloid accumulation is 'absolutely not the cause of Alzheimer's disease' and that the amyloid hypothesis is entirely flawed contradicts extensive genetic, biochemical, and clinical trial evidence. Dominant mutations causing early-onset familial Alzheimer's disease (in APP, PSEN1, and PSEN2) and gene dosage effects in Down syndrome all directly alter amyloid-beta (Aβ) production or processing, establishing that Aβ dyshomeostasis is a key initiating causative factor in AD pathogenesis. While the original linear 'amyloid cascade hypothesis' has evolved—recognizing that Alzheimer's is multifactorial and that downstream tau neurofibrillary tangles, neuroinflammation, and synaptic loss drive cognitive decline—Aβ is well established as a critical upstream driver, and recently approved monoclonal antibodies that clear Aβ (e.g., lecanemab, donanemab) demonstrate statistically significant slowing of clinical disease progression.

0:19:44supportedhighWhy 1 in 2 Seniors Get Alzheimer's (And How to Be the Except

A Cochrane analysis of 17 studies encompassing 20,342 individuals on beta-amyloid-lowering drugs for Alzheimer's found the clinical benefit was trivial while 20% to 25% of patients developed brain hemorrhages, brain swelling, or death.

"A Cochrane analysis was published about two months ago. This was an analysis of the 17 top studies that evaluated the effectiveness of the drugs that do indeed lower beta-amyloid in the brain. The study that involved 20,342 individuals, each study lasting about 18 months, looked at two things: risk and benefit... What they found was the benefit was zilch. That's not the word they used; the word they used was "trivial." They don't work. And the risk was really high: 20 to 25% of these people on these drugs develop brain hemorrhages, and/or brain swelling, or even death" (said at 0:19:44)

The speaker accurately describes a Cochrane systematic review and meta-analysis (PMID 41985900) evaluating amyloid-beta-targeting monoclonal antibodies for early Alzheimer's disease and mild cognitive impairment. The review included exactly 17 randomized controlled trials with 20,342 participants, most lasting 18 months. The Cochrane authors concluded that these drugs produce 'little to no difference' (standardized mean differences of 0.09 to 0.12, commonly characterized as trivial/sub-clinical) in cognitive function, dementia severity, and functional ability at 18 months, while significantly increasing the risks of amyloid-related imaging abnormalities (ARIA), which encompass brain oedema (swelling) and micro-/macro-haemorrhages (bleeding), as well as serious adverse events.

0:24:13supportedvery lowWhy 1 in 2 Seniors Get Alzheimer's (And How to Be the Except

Destructive M1 microglia downregulate mitochondrial function and primarily rely on glycolysis for energy production.

"The M1 destructive microglial cell does not use mitochondria to any significant degree; it's using glycolysis. So its energy production is much less efficient, much less ATP produced." (said at 0:24:13)

Preclinical cell and animal studies support the claim that pro-inflammatory (M1) microglial polarization involves immunometabolic reprogramming characterized by reduced mitochondrial oxidative metabolism and a switch toward aerobic glycolysis as the primary mode of energy production. Because glycolysis produces substantially fewer moles of ATP per mole of glucose compared to mitochondrial oxidative phosphorylation, energy production via this pathway is less biochemically efficient.

0:28:10contradictedhighWhy 1 in 2 Seniors Get Alzheimer's (And How to Be the Except

Higher blood levels of phosphorylated tau 217 (p-tau217) serve as a biomarker indicating the loss of synapses in the brain.

"the higher the level of this p-tau217 blood test, that is an indication of loss of synapses. It is therefore—and what is causing loss of the synapses? Activation of the microglial cells." (said at 0:28:10)

The speaker claims that higher blood levels of p-tau217 indicate a loss of synapses in the brain. In Alzheimer's disease biomarker frameworks and extensive clinical literature, phosphorylated tau (including p-tau217) specifically reflects amyloid-beta plaque pathology and neurofibrillary tau tangle pathology (specifically tau phosphorylation/secretion in response to amyloidosis), not synaptic loss directly. Synaptic loss is measured by distinct fluid biomarkers (such as neurogranin, NPTX2, synaptotagmin, or SV2A PET imaging) or markers of neurodegeneration (such as neurofilament light chain [NfL]), whereas p-tau217 specifically indicates amyloid and tau pathology.

0:32:28needs contexthighWhy 1 in 2 Seniors Get Alzheimer's (And How to Be the Except

Being heterozygous for the APOE4 allele confers a five-fold increased risk of Alzheimer's disease, and being homozygous increases the risk 12-fold.

"if I'm heterozygous I have a five-fold increased risk. If I have two of them, homozygous, my risk for Alzheimer's may increase 12-fold." (said at 0:32:28)

Large meta-analyses establish that carrying APOE ε4 significantly increases the risk of Alzheimer's disease in a dose-dependent manner. In Caucasian populations compared to ε3/ε3 individuals, heterozygosity (ε3/ε4) is associated with an approximate 3-fold increased risk (odds ratio ~3.2, 95% CI 2.8–3.8, though reaching ~5.6 in Japanese cohorts), while homozygosity (ε4/ε4) increases risk approximately 12- to 15-fold (OR ~14.9 in Caucasians, 95% CI 10.8–20.6). The speaker's figures of 5-fold and 12-fold closely reflect this well-established gene-dose effect, with exact odds ratios varying somewhat by ancestral background, sex, and age.

0:34:45supportedmoderateWhy 1 in 2 Seniors Get Alzheimer's (And How to Be the Except

In American adults, 60% of daily caloric intake comes from ultra-processed foods.

"we live in a country where in adults 60% of calories are coming from these frankenfoods, as the term you've used in the past, these ultra-processed foods that represent a clear and present danger to your brain's destiny." (said at 0:34:45)

Nationally representative dietary data from the National Health and Nutrition Examination Survey (NHANES) consistently show that ultra-processed foods contribute approximately 54% to 58% of total daily energy intake among US adults (rising from 53.5% in 2001–2002 to 57.0%–57.9% in recent survey waves). Stating that ~60% of daily caloric intake comes from ultra-processed foods is well-supported by national dietary surveillance.

0:38:27supportedmoderateWhy 1 in 2 Seniors Get Alzheimer's (And How to Be the Except

A 2024 study in The Lancet examining 14 modifiable risk factors showed that addressing them is associated with about a 50% reduced risk of developing dementia.

"a study appearing in The Lancet in 2024 that looked at 14 modifiable factors and indicated that attention to these 14 modifiable factors is associated with about a 50% reduced risk for developing dementia." (said at 0:38:27)

The 2024 Lancet Commission report on dementia prevention, intervention, and care (Livingston et al., 2024, PMID 39096926) updated its life-course model from 12 to 14 modifiable risk factors (adding untreated vision loss and high LDL cholesterol). The report calculated that eliminating these 14 risk factors across the life course accounts for a global population attributable fraction (PAF) of approximately 45% (with subsequent regional analyses reporting up to 59.5% in lower- and middle-income regions, PMID 40823285), matching the speaker's statement of 'about a 50%' potential reduction.

0:39:42supportedmoderateWhy 1 in 2 Seniors Get Alzheimer's (And How to Be the Except

A randomized trial led by Dr. Kirk Erickson showed that aerobic exercise for one year increased the volume of the brain's hippocampus and improved cognitive function.

"from a Dr. Kirk Erickson, who randomized a group of just over 100 individuals: one group stretched, one group aerobically exercised. After one year, he did two things—he did a cognitive assessment, and he actually did three things: he measured their BDNF (we'll talk about that in a minute), and he actually measured the size using an MRI of their memory center in the brain. And he was first to demonstrate that this intervention, this program that you put people on, was associated with an increase in size of the brain's memory center, a preservation, in fact an improvement of cognitive function, just because these people exercised." (said at 0:39:42)

The speaker accurately summarizes the randomized controlled trial led by Dr. Kirk I. Erickson published in PNAS in 2011 (n=120 older adults). The study compared 1 year of moderate-intensity aerobic exercise against a stretching control group, using MRI to measure brain volumes along with tests of spatial memory and serum BDNF levels. The aerobic exercise intervention increased anterior hippocampal volume by approximately 2% and improved spatial memory, with the volume increase associated with higher serum BDNF levels.

0:40:25supportedmoderateWhy 1 in 2 Seniors Get Alzheimer's (And How to Be the Except

A 20-week trial by Rudolph Tanzi and Dean Ornish in 51 patients with Alzheimer's disease demonstrated that comprehensive lifestyle changes stopped cognitive decline in 70% of participants, with many improving.

"Rudolph Tanzi at Harvard, along with Dean Ornish, published a study last year demonstrating an interventional trial on 51 individuals—not a huge trial—over a 20-week period of time demonstrating that when they changed people's diets, allowed them to exercise regularly or invited them to exercise regularly, reduced their stress, these are individuals with Alzheimer's disease diagnosed, that their cognitive function didn't slow in its decline; by and large, it stopped declining completely. And in fact, this is in 70% of their interventional people. In many of them, it actually improved." (said at 0:40:25)

The speaker accurately describes a randomized controlled trial published in 2024 by Dean Ornish, Rudolph Tanzi, and colleagues in Alzheimer's Research & Therapy (PMID: 38849944). The study enrolled 51 patients with mild cognitive impairment or early dementia due to Alzheimer's disease in a 20-week multidomain intensive lifestyle intervention (plant-based diet, regular exercise, stress management, and support groups). The trial found that participants in the intervention group showed stabilization or improvement across several cognitive and functional measures (such as CGIC, CDR Global, and ADAS-Cog), whereas the control group experienced progression.

0:41:30unverifiedlowWhy 1 in 2 Seniors Get Alzheimer's (And How to Be the Except

A meta-analysis review of 36 interventional trials with nearly 6,000 participants found that the combination of aerobic and resistance training provides the greatest cognitive benefit, especially in individuals age 65 or older and those with existing cognitive impairment.

"a study that was a review of 36 interventional trials where they put people on these programs, and it was close to 6,000 individuals. And their conclusion was: is it aerobics, is it resistance training? Their conclusion was it is both. It's the combination that seems to work best... And what Jiang and the other researchers in that report noticed was that the best bang for the buck, in other words the best response, was in individuals who were age 65 or older—you and me—and also those individuals who already had some cognitive impairment." (said at 0:41:30)

A specific meta-analysis by Jiang et al. encompassing exactly 36 interventional trials and nearly 6,000 participants evaluating the combined effects of aerobic and resistance exercise across age groups and baseline cognitive status could not be located in the search. This does not prove the claim or publication does not exist, but no matching published record was verified.

0:41:45supportedhighWhy 1 in 2 Seniors Get Alzheimer's (And How to Be the Except

Muscle tissue functions as an endocrine gland by secreting chemicals that regulate metabolism and positively influence brain health.

"when we do resistance training, we're building muscles, which is really important because muscle tissue is an endocrine gland secreting various chemicals that ultimately positively influence brain health. So the muscles make chemicals that go elsewhere in the body; therefore, it's an endocrine gland more involved in regulating metabolism." (said at 0:41:45)

Extensive exercise physiology and endocrinology literature confirms that skeletal muscle functions as an endocrine organ. In response to contraction (such as resistance or aerobic exercise), muscle tissue synthesizes and secretes diverse signaling molecules collectively called myokines (e.g., irisin, IL-6, BDNF, cathepsin B). These humoral factors enter the circulation to regulate systemic metabolism (including glucose and lipid homeostasis in the liver, pancreas, and adipose tissue) and cross or influence the blood-brain barrier to promote neuroplasticity, cognitive function, and brain health.

0:49:43supportedmoderateWhy 1 in 2 Seniors Get Alzheimer's (And How to Be the Except

Lipopolysaccharide (LPS) leaking from the gut challenges immune cells to produce inflammatory cytokines that cross to the brain and stimulate microglial cells to become neurodestructive.

"What do these immune cells do now that they are challenged with various chemicals like LPS—people may have heard of that, lipopolysaccharide? They increase their production of these inflammatory cytokines. If we go back to our original conversation early in this interview, we remember that cytokines, these inflammatory chemicals, make their way to the brain and stimulate our microglial cells to shift from being supportive brain defenders to being destructive." (said at 0:49:43)

The biological pathway described by the speaker is well established in neuroimmunology and gut-brain axis research. Increased intestinal permeability allows lipopolysaccharide (LPS, an endotoxin from gram-negative bacterial cell walls) into systemic circulation, where it stimulates peripheral immune cells to produce pro-inflammatory cytokines (such as TNF-α, IL-1β, and IL-6). These inflammatory signals access the central nervous system via blood-brain barrier transport or neural signaling pathways, triggering microglia to shift from a homeostatic state to a reactive, neurotoxic phenotype that can damage synapses and neurons.

0:51:55needs contextlowWhy 1 in 2 Seniors Get Alzheimer's (And How to Be the Except

A prospective study following 1,111 individuals over 12.7 years found that consuming an average of one serving of ultra-processed food per day was associated with a 13% increased risk of Alzheimer's disease.

"one study that was published in the Journal of Prevention of Alzheimer's—can you imagine, a Journal of Prevention of Alzheimer's? Be still my beating heart. And this study that came out last year followed a group of 1,111 individuals over a period of 12.7 years and basically asked these folks during this 12.7 year, during the period of time that we're going to study you, what do you eat? So they kept a food frequency diary. What did they find? They found that those individuals who consumed as an average one serving per day of ultra-processed foods experienced a 13% increased risk of Alzheimer's disease." (said at 0:51:55)

A prospective study from the Framingham Heart Study published in The Journal of Prevention of Alzheimer's Disease (follow-up mean 12.7 years) did find that each additional serving per day of ultra-processed food was associated with a 13% higher risk of Alzheimer's disease (HR = 1.13, 95% CI: 1.03–1.25). However, this finding was specific to participants who were younger than 68 years at baseline; no significant association was observed among individuals aged 68 or older at baseline.

0:52:55needs contextlowWhy 1 in 2 Seniors Get Alzheimer's (And How to Be the Except

In the same prospective study, consuming 10 or more servings of ultra-processed foods per day was associated with a 270% increased risk of Alzheimer's disease.

"they found that in those individuals who consumed 10 or more servings of ultra-processed foods a day... Their risk is increased 270%. That's of a disease for which we have no meaningful pharmaceutical treatment." (said at 0:52:55)

The claim accurately reflects findings from an analysis of the Framingham Heart Study Offspring cohort published in 2025 (PMID: 39863327), but requires two qualifications: 1) An adjusted hazard ratio of 2.71 represents a 2.7-fold risk (a 171% relative increase), which is often conflated with a 270% increase; and 2) this association was observed exclusively in the subgroup of participants aged <68 years at baseline (HR 2.71, 95% CI 1.18–6.24), with no significant association detected among those aged ≥68 years.

0:53:56supportedlowWhy 1 in 2 Seniors Get Alzheimer's (And How to Be the Except

Short-chain fatty acids produced by gut bacteria travel to the brain and regulate gene expression.

"it's the lack of production of certain metabolites, products of these bacteria that make their way to the brain, these short-chain fatty acids that are important for gene expression regulation. What did I just say? That our gut bacteria are regulating our gene expression, our life code. I better take good care of my gut bacteria because they have a big, they have a very important job. They are determining gene expression throughout my body and, yes, even in my brain, for crying out loud." (said at 0:53:56)

The claim accurately describes a recognized mechanistic pathway within the gut-brain axis: short-chain fatty acids (SCFAs) such as butyrate, acetate, and propionate are produced by bacterial fermentation in the colon, can cross the blood-brain barrier, and act as epigenetic regulators (notably via histone deacetylase [HDAC] inhibition) to alter central nervous system gene expression. However, the evidence base is graded as low certainty because it is primarily derived from preclinical animal models, in vitro assays, and pharmacological administration of SCFAs rather than direct in vivo human interventional data.

0:57:25supportedmoderateWhy 1 in 2 Seniors Get Alzheimer's (And How to Be the Except

Trichloroethylene (TCE) is an industrial cleaner and dry-cleaning solvent that contaminates groundwater, targets mitochondria, and is associated with the development of Parkinson's disease.

"what Dr. Dorsey made very clear is that we are exposed to a variety of toxins these days in our environment that directly target mitochondria and therefore can manifest as things like Parkinson's. As you discussed in your interview of Dr. Dorsey, he's really very much fixated on this trichloroethylene, which had been used—industrial cleaner, dry cleaning fluid—makes its way into water, you know, and there are places where groundwater is still contaminated by TCE." (said at 0:57:25)

The speaker's assertions accurately reflect the established scientific literature and the specific work of Dr. Ray Dorsey and colleagues. Trichloroethylene (TCE) is an industrial solvent and dry-cleaning chemical known to contaminate groundwater and soil. Mechanistic and preclinical studies show that TCE selectively inhibits mitochondrial complex I, driving oxidative stress and dopaminergic neurodegeneration in the substantia nigra. Observational and epidemiological studies have linked occupational, military (e.g., Camp Lejeune), and environmental TCE exposure to an elevated risk of Parkinson's disease.

0:58:05supportedhighWhy 1 in 2 Seniors Get Alzheimer's (And How to Be the Except

MPTP is a mitochondrial-targeting contaminant of illicit intravenous drugs from the 1980s that causes Parkinson's disease.

"this MPTP contaminant of this IV drug that people were using in the '80s and getting Parkinson's because MPTP targets the mitochondria." (said at 0:58:05)

In 1982-1983, Langston and colleagues identified that 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP), a contaminant produced during the illicit synthesis of the meperidine analog MPPP ('synthetic heroin'), caused severe, irreversible parkinsonism in intravenous drug users. Subsequent mechanistic research established that its metabolite (MPP+) accumulates in dopaminergic neurons and selectively inhibits mitochondrial respiratory chain complex I, leading to dopaminergic neuronal death in the substantia nigra.

0:58:55supportedhighWhy 1 in 2 Seniors Get Alzheimer's (And How to Be the Except

Over 70 countries globally have banned or significantly restricted the agricultural use of the herbicide paraquat.

"The good news is that 70 countries around the globe, because it is such a devastating toxic exposure, paraquat, have banned or significantly reduced the use of paraquat in agriculture." (said at 0:58:55)

A 2025 systematic review of global paraquat regulations identified that at least 74 countries do not authorise paraquat in their markets through bans, phase-outs, and market withdrawals, confirming the speaker's claim that over 70 countries have banned or significantly restricted its agricultural use due to human toxicity concerns.

0:59:30supportedmoderateWhy 1 in 2 Seniors Get Alzheimer's (And How to Be the Except

Paraquat is a mitochondrial toxin whose exposure is associated with an increased risk of Parkinson's disease.

"So we've had to turn to the use of paraquat, a mitochondrial toxin exposure to which is associated with increased risk of Parkinson's, to treat the weeds in our modern agriculture." (said at 0:59:30)

The speaker accurately states that paraquat is a mitochondrial toxin and that exposure to it is associated with an increased risk of Parkinson's disease. Systematic reviews and meta-analyses of observational studies demonstrate a statistically significant positive association between paraquat exposure and Parkinson's disease risk (e.g., OR 1.64, 95% CI: 1.27–2.13 in Tangamornsuksan et al., 2019; and a 25% increased risk in Vaccari et al., 2019). Mechanistic toxicological research confirms that paraquat exerts neurotoxicity by generating reactive oxygen species and inducing mitochondrial dysfunction in dopaminergic neurons.

0:59:42needs contextlowWhy 1 in 2 Seniors Get Alzheimer's (And How to Be the Except

Paraquat is used experimentally in research laboratories to induce Parkinson's disease in non-human primates.

"Paraquat is used experimentally to create Parkinson's in primates in research laboratories" (said at 0:59:42)

Paraquat is widely used in laboratory research as a neurotoxin to model Parkinson's disease (PD) mechanisms and dopaminergic degeneration, and it has been administered to non-human primates in experimental research assessing striatal dopaminergic deficits. However, the claim requires qualification: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is the standard and predominant neurotoxin used to create full parkinsonian syndromes in non-human primates, whereas paraquat is primarily utilized in rodent and in vitro cellular models of PD.

1:00:15supportedvery lowWhy 1 in 2 Seniors Get Alzheimer's (And How to Be the Except

Glyphosate functions as a mitochondrial toxin.

"glyphosate itself, the active ingredient in Roundup—buy it at the hardware store and, you know, spray it around your vegetables, I'm telling you not to do that—is similarly a mitochondrial toxin." (said at 1:00:15)

Preclinical and mechanistic evidence demonstrates that glyphosate and glyphosate-based herbicides induce mitochondrial dysfunction, typically alongside oxidative stress, altered mitochondrial membrane potential, and impaired cellular bioenergetics across various animal and in vitro models. A 2022 systematic review of glyphosate neurotoxicity identified mitochondrial dysfunction and oxidative stress as prominent mechanisms leading to cellular damage and death. However, certainty is graded very low because available data derive from in vitro and animal experimental models, with some tissue-specific variability regarding the potency of pure glyphosate compared to formulated commercial products containing surfactant adjuvants.

1:02:11supportedlowWhy 1 in 2 Seniors Get Alzheimer's (And How to Be the Except

Inhaled PM2.5 particulate matter from sources like wildfire smoke increases systemic pro-inflammatory cytokines that travel to the brain and shift microglia into a destructive phenotype.

"These particles, these PM2.5s, are powerfully pro-inflammatory, meaning they increase the cytokines in our bodies that make their way to the brain and will shift our brain defenders, microglia cells, to becoming brain destroyers." (said at 1:02:11)

Extensive preclinical, cellular, and review literature supports the mechanistic pathway described by the speaker. Inhalation of fine particulate matter (PM2.5) induces pulmonary and systemic inflammation characterized by elevated circulating pro-inflammatory cytokines (such as IL-1β, IL-6, and TNF-α). These systemic mediators transmit inflammatory signals across the blood-brain barrier via the lung-brain axis, triggering microglial activation and phenotypic polarization toward a pro-inflammatory, neurotoxic (e.g., M1-like) state that contributes to neurodegeneration. Certainty is rated as low because direct mechanistic tracing of systemic cytokines driving microglial phenotype shifts relies primarily on in vitro and animal models.

1:02:46supportedmoderateWhy 1 in 2 Seniors Get Alzheimer's (And How to Be the Except

PM2.5 particles can be inhaled directly through the nose into the brain and induce neuroinflammation.

"And also, the PM2.5s themselves can be inhaled and make their way through the nose into the brain directly and can induce inflammation." (said at 1:02:46)

Toxicological, animal, and human post-mortem studies demonstrate that fine particulate matter (PM2.5), particularly its ultrafine nanoparticle fraction, can bypass the systemic circulation and translocate directly from the nasal cavity into the central nervous system via the olfactory mucosal and nerve pathway. Once inside the brain, these particles activate microglia and astrocytes, triggering oxidative stress and neuroinflammation.

1:02:52needs contextmoderateWhy 1 in 2 Seniors Get Alzheimer's (And How to Be the Except

Systemic inflammation causes microglia to polarize into a pro-inflammatory M1 phenotype that releases damaging cytokines, creating a feed-forward cycle that activates further microglia.

"inflammation from any source will shift the microglia to becoming their M1 destructive phenotype, we call it. That is a pro-inflammatory phenotype, meaning that once those microglia shift to being the evil twin... they are spitting out more and more of these damaging cytokines in the brain that further target other good microglia cells and shift them to being on the dark side" (said at 1:02:52)

The claim captures the traditional paradigm of neuroinflammation—where systemic inflammatory signals trigger microglial activation, cytokine release, and self-propagating neuroinflammatory cascades—but frames it using an outdated, oversimplified binary model. While preclinical and clinical studies confirm that peripheral inflammation promotes pro-inflammatory microglial responses and cytokine cascades, contemporary neuroscience (via single-cell transcriptomics and multi-omics) has discarded the strict binary 'M1 (destructive/pro-inflammatory) vs M2 (protective/anti-inflammatory)' classification. Microglia in vivo exhibit heterogeneous, multidimensional, and highly dynamic transcriptomic and functional states rather than a fixed 'M1 evil twin' switch.

1:07:42overstatedlowWhy 1 in 2 Seniors Get Alzheimer's (And How to Be the Except

Interventional trials using lifestyle modification have proven effective in improving cognitive outcomes in individuals with established Alzheimer's disease.

"interventional trials using lifestyle modification have proven effective even in individuals with established Alzheimer's disease." (said at 1:07:42)

While a 2024 randomized controlled phase 2 trial by Ornish et al. (n=51) demonstrated improvements or stabilization in cognitive and functional measures (such as CGIC, CDR-SB, and CDR-Global) following a 20-week intensive multidomain lifestyle intervention in patients with mild cognitive impairment or early dementia due to Alzheimer's disease, stating that lifestyle modification has 'proven effective' in established Alzheimer's disease overstates the evidence. The existing evidence is preliminary, derived from a small sample over a short duration, and most large multidomain lifestyle trials (e.g., FINGER) have focused on dementia prevention in at-risk older adults rather than treatment of established Alzheimer's disease.

1:08:25supportedmoderateWhy 1 in 2 Seniors Get Alzheimer's (And How to Be the Except

An interventional trial published in the New England Journal of Medicine showed that a GLP-1 receptor agonist stabilized Parkinson's disease.

"We've seen an incredible interventional trial published in the New England Journal of Medicine where Parkinson's was stabilized. I think GLP-1s have a future in the brain health arena." (said at 1:08:25)

A phase 2, randomized, double-blind, placebo-controlled trial published in the New England Journal of Medicine in April 2024 (the LIXIPARK trial, n=156) evaluated the GLP-1 receptor agonist lixisenatide in patients with early Parkinson's disease. At 12 months, motor disability scores (MDS-UPDRS part III) showed essentially no progression in the lixisenatide group (change of -0.04 points) compared to worsening in the placebo group (+3.04 points, p=0.007), demonstrating stabilization of motor disability progression over the 1-year study period.

0:12:25supportedhighParkinson's Is a Man-Made Disease: The Chemicals Linked to a

More than 70 countries around the world, including China, have banned or curtailed the use of the herbicide paraquat.

"72 countries or maybe more around the world have either banned it outright or significantly curtailed its use, but that's not the case in America." (said at 0:12:25)

Published policy analyses and reviews confirm that approximately 70 countries (and over 67 countries with complete bans alone) have banned or phased out paraquat, including China, the European Union member states, the UK, Switzerland, and Brazil, while the pesticide remains approved and widely used in the United States.

0:16:17unverifiedvery lowParkinson's Is a Man-Made Disease: The Chemicals Linked to a

In 2018, approximately 11 million pounds of paraquat were used in the United States.

"My last citation that I could find was 2018; I think data is coming out this year from the US Geological Survey, but that was 11 million pounds of paraquat used." (said at 0:16:17)

No retrieved publication or dataset from the fetched records contained the specific 2018 US Geological Survey (USGS) estimate of approximately 11 million pounds of paraquat applied in the United States. While USGS National Water Quality Assessment (NAWQA) data and related environmental health literature track agricultural paraquat use in the U.S., the specific figure cited could not be confirmed within the available fetched literature. This does not prove the claim false, but leaves it unverified based on the fetched records.

0:33:30supportedhighParkinson's Is a Man-Made Disease: The Chemicals Linked to a

In 1982 to 1983, Dr. William Langston discovered that MPTP, a contaminant in synthetic heroin, induced immediate Parkinsonism in exposed individuals.

"Back in 1982 into '83, Dr. Langston, a neurologist at Stanford, was confronted by individuals in the emergency room who had suddenly developed Parkinson's seemingly out of the blue. Detective work he he engaged revealed that they had all gotten a a drug that was uh synthetic heroin... Anyway, so it turns out that they discovered that a contaminant, if you will, of the synthetic heroin, MPTP, induced Parkinsonism immediately in these people" (said at 0:33:30)

In 1982–1983, Dr. J. William Langston and colleagues identified that 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a chemical byproduct/contaminant in a synthetic heroin analog (MPPP), caused rapid and severe parkinsonism in young drug users in Northern California. Their landmark case report was published in Science in 1983 and led to widespread understanding of MPTP neurotoxicity and animal models of Parkinson's disease.

0:34:28supportedvery lowParkinson's Is a Man-Made Disease: The Chemicals Linked to a

Examination of the brain of an MPTP-exposed patient 13 years later revealed an ongoing chronic immune response by activated microglial cells in the substantia nigra.

"And but what was interesting is 13 years later, one of the patients passed away and he examined the brain of this patient. What he found was an ongoing immune response by cells in the brain called the microglia cells digesting away the part of the brain that's the center of Parkinson's, the substantia nigra." (said at 0:34:28)

A landmark postmortem case series by Langston et al. (1999) examined the brains of three patients who had developed severe parkinsonism after accidental MPTP exposure, with survival times ranging from 3 to 16 years post-exposure (including a patient surviving ~12–16 years). Neuropathological examination demonstrated severe loss of pigmented dopaminergic neurons in the substantia nigra accompanied by marked gliosis, extraneuronal melanin, and activated microglia clustering around degenerating nerve cells, indicating an ongoing, self-perpetuating neuroinflammatory/neurodegenerative process years after the initial toxic insult. As this evidence comes from a small postmortem case series (n=3), the GRADE certainty is very low.

0:38:08supportedvery lowParkinson's Is a Man-Made Disease: The Chemicals Linked to a

MPP+, the active metabolite of MPTP, causes mitochondrial toxicity by damaging complex I of the electron transport chain.

"I think primarily what happened was there was a mitochondrial injury, a mitochondriopathy was induced, complex I of electron transport was was damaged by this assault, by this MPP+ actually, that the metabolite of MPTP." (said at 0:38:08)

The host's statement is fully supported by scientific literature. MPP+ (1-methyl-4-phenylpyridinium) is the active toxic metabolite of MPTP. Once inside dopaminergic neurons, MPP+ concentrates within the mitochondria where it binds to and inhibits complex I (NADH:ubiquinone oxidoreductase) of the electron transport chain. This inhibition impairs mitochondrial respiration, depletes ATP, and generates reactive oxygen species, leading to mitochondrial dysfunction (mitochondriopathy) and cell death. Although this mechanism is highly established in neurotoxicology, the certainty is graded as very low because the evidence is derived from in vitro and animal models of Parkinson's disease.

0:41:00supportedmoderateParkinson's Is a Man-Made Disease: The Chemicals Linked to a

Type 2 diabetics have approximately a 40% increased risk of developing Parkinson's disease.

"type 2 diabetics have about perhaps a 40% increased risk of of Parkinson's?" (said at 0:41:00)

The speaker's statement that individuals with diabetes have approximately a 40% increased risk of developing Parkinson's disease is well supported by systematic reviews and meta-analyses of population-based cohort studies. Earlier landmark meta-analyses reported a 37% to 38% increased relative risk (e.g., RR = 1.38, 95% CI: 1.18–1.62 in Yue et al., 2016; RR = 1.37, 95% CI: 1.21–1.55 in Cereda et al., 2011). More recent comprehensive meta-analyses including tens of millions of participants estimate this elevated relative risk between 22% and 29% (e.g., RR = 1.27, 95% CI: 1.20–1.35 in a 2023 meta-analysis of 15 cohort studies by European Journal of Epidemiology).

1:03:45overstatedhighParkinson's Is a Man-Made Disease: The Chemicals Linked to a

The Lancet report identified 14 modifiable risk factors for dementia.

"Yeah, you know that Lancet report was actually quite interesting because they identified 14 modifiable factors and most of them dealt with our metabolism." (said at 1:03:45)

The speaker's statement bundles two claims: 1. The Lancet report identified 14 modifiable risk factors for dementia: This is SUPPORTED. The 2024 Lancet Commission report on dementia prevention, intervention, and care updated its model to 14 modifiable risk factors (adding high LDL cholesterol and untreated vision loss to the 12 factors from the 2020 report). 2. Most of them dealt with metabolism: This is CONTRADICTED. Only a minority of the 14 factors are primary metabolic/cardiometabolic markers (e.g., diabetes, obesity, high LDL cholesterol, hypertension). The majority comprise sensory, cognitive, behavioral, and environmental factors, including lower early-life education, hearing loss, vision loss, traumatic brain injury, depression, social isolation, smoking, excessive alcohol consumption, physical inactivity, and air pollution. Following the rubric to score bundled assertions by their least accurate part, the overall verdict is overstated/contradicted.

1:03:53supportedmoderateParkinson's Is a Man-Made Disease: The Chemicals Linked to a

Only about 6% of American adults are metabolically healthy, meaning roughly 94% have at least one marker of metabolic syndrome.

"about 6% of American adults is metabolically intact, meaning about 94% of American adults has at least one issue related to metabolic syndrome" (said at 1:03:53)

A nationally representative study of 55,081 U.S. adults from the National Health and Nutrition Examination Survey (NHANES 1999–2018), published in the Journal of the American College of Cardiology (O'Hearn et al., 2022), evaluated cardiometabolic health across five components: adiposity, blood glucose, blood lipids, blood pressure, and clinical cardiovascular disease. In 2017–2018, only 6.8% (95% CI: 5.4%–8.1%) of U.S. adults had optimal levels across all cardiometabolic components, meaning approximately 93.2% (roughly 94%) had at least one intermediate or poor cardiometabolic risk marker.

0:01:34supportedmoderateYour Anxiety Is a Metabolic Problem, Not a Mental One | Dr.

Dysregulated microglial cells can drive neuroinflammation and neurodegeneration long before clinical symptoms appear.

"These are the brain's immune cells. And when they're balanced, they are protecting. They are repairing. Well, when they're dysregulated, and we can talk about why that happens, and we do talk about it in the book, they can drive inflammation and lead to brain degeneration, often long before symptoms appear." (said at 0:01:34)

The host's statement accurately reflects established neurobiology. Microglia serve as the resident immune and surveillance cells of the central nervous system, maintaining homeostatic, reparative, and protective functions in health. When chronically dysregulated, sustained microglial activation releases pro-inflammatory cytokines and neurotoxic mediators that drive neuroinflammation, synaptic loss, and neurodegeneration. Longitudinal PET imaging (e.g., TSPO radioligands) and cerebrospinal fluid biomarker studies confirm that microglial dysregulation and neuroinflammatory changes are detectable in preclinical stages of neurodegenerative disorders (such as Alzheimer's disease) and correlate with subsequent longitudinal cognitive and structural decline well before clinical symptoms manifest.

0:28:13unverifiedvery lowYour Anxiety Is a Metabolic Problem, Not a Mental One | Dr.

Stroboscopic 40 Hz flashing light devices can cause side effects including nausea and headaches.

"Most use what's called stroboscopic light, and that's the type of light that flashes then you can see the flashing and that can cause nausea, it can cause headaches" (said at 0:28:13)

No published records detailing the specific adverse event rates (such as nausea and headache) associated with visible stroboscopic 40 Hz light stimulation devices were successfully fetched within the search limit. Consequently, the claim cannot be independently verified from the retrieved records.

0:28:20overstatedlowYour Anxiety Is a Metabolic Problem, Not a Mental One | Dr.

Non-stroboscopic 40 Hz light stimulation from Optoceutics (the EVY light) achieves a 94% adherence rate and produces significant improvements in mood, energy, focus, sleep, and memory.

"And that's why this company sees a 94% adherence rate and significant improvements across various metrics including mood, energy, focus, sleep, and memory. And the light is called the EVY light." (said at 0:28:20)

While non-stroboscopic 40 Hz light stimulation using invisible spectral flicker (developed by Optoceutics for the EVY light) was designed to improve tolerability and has demonstrated high adherence in pilot feasibility testing (e.g., >86% in a pilot clinical trial), the claim that it produces significant improvements across mood, energy, focus, sleep, and memory is overstated. In a double-blind, randomized, placebo-controlled pilot trial of 40 Hz invisible spectral flicker in patients with Alzheimer's disease (PMID 36776073), only preliminary exploratory trends in cognition and volumetric MRI were observed, and the authors noted that efficacy must be tested in larger-scale clinical trials. Published trials have not established statistically significant clinical improvements across mood, energy, focus, sleep, and memory.

0:28:50needs contexthighYour Anxiety Is a Metabolic Problem, Not a Mental One | Dr.

Between 25% and 28% of people carry an MTHFR polymorphism.

"You know, it's interesting you mentioned B vitamins and methylated B vitamins for those of us, the 25 to 28% of us who have this MTHFR polymorphism." (said at 0:28:50)

The speaker's figure of 25% to 28% likely conflates allele frequency or specific homozygous/heterozygous subpopulations with the overall carrier rate. In reality, carrying at least one variant allele of the MTHFR gene (such as C677T or A1298C) is much more common, occurring in over 50% to 60% of many populations (and up to 87% across all variants). Conversely, homozygous inheritance for the most clinically discussed variant (C677T, genotype TT) varies widely by ancestry, from ~1% in populations of African descent to ~10–14% in non-Hispanic whites and ~20% or more in Hispanic populations. An allele frequency of ~25–35% is common for the 677T allele in certain groups, but referring to 25–28% of individuals as 'carrying' an MTHFR polymorphism is an imprecise representation of population genetics.

0:30:15supportedvery lowYour Anxiety Is a Metabolic Problem, Not a Mental One | Dr.

Elevated homocysteine is metabolized into homocysteic acid, which acts as a mitochondrial toxin.

"Because when our homocysteine levels do go up, it's metabolized into homocysteic acid, which is a mitochondrial toxin." (said at 0:30:15)

Preclinical and in vitro studies show that homocysteine is metabolized/oxidized to homocysteic acid (HCA), an excitatory amino acid and neurotoxin. In cellular and animal models, HCA causes direct mitochondrial damage, including selective inhibition of mitochondrial respiratory chain complex I, disruption of mitochondrial membrane potential, and enhanced production of mitochondrial reactive oxygen species. Certainty is rated very low because this mechanistic relationship is established in laboratory cell cultures and rodent models rather than clinical human trials.

0:46:32needs contextmoderateYour Anxiety Is a Metabolic Problem, Not a Mental One | Dr.

Circulating inflammatory cytokines cross the blood-brain barrier and polarize microglial cells away from supportive housekeeping states and toward destructive states.

"Well, the other thing is the fact that these inflammatory cytokines readily get through the blood-brain barrier and then influence the brain's immune cells, the microglia, to polarize them away from being supportive and towards being destructive." (said at 0:46:32)

The speaker accurately describes the downstream functional consequence—systemic inflammatory cytokines activate and shift microglia from homeostatic/supportive surveillance phenotypes toward reactive, neurotoxic phenotypes that exacerbate neuroinflammation and tissue damage. However, the claim that cytokines 'readily get through' the blood-brain barrier (BBB) requires qualification. Cytokines are large hydrophilic proteins (~15–25 kDa) that do not passively diffuse across an intact BBB; rather, they communicate with the central nervous system through specialized saturable transport systems, circumventricular organs, direct activation of brain endothelial cells (which transduce signals centrally), or when pathological systemic inflammation compromises BBB integrity.

0:46:46supportedlowYour Anxiety Is a Metabolic Problem, Not a Mental One | Dr.

Increased gut permeability from dysbiosis allows messengers across the blood-brain barrier, making individuals more prone to neurodegenerative disorders like Parkinson's and Alzheimer's.

"That's a fundamental mechanism that then allows us to understand why is it that people with dysbiosis and therefore increased gut permeability are more prone to neurodegenerative conditions like Parkinson's and Alzheimer's. Now we get it. These are the messengers that make their way across the blood-brain barrier." (said at 0:46:46)

Extensive literature on the microbiota-gut-brain axis describes the proposed pathway where gut dysbiosis increases intestinal permeability (often termed a 'leaky gut'), allowing microbial products (such as lipopolysaccharides/endotoxins) and pro-inflammatory cytokines into the systemic circulation. These mediators promote systemic inflammation, disrupt blood-brain barrier (BBB) integrity, and cross into the central nervous system to induce neuroinflammation, protein misfolding, and neurodegeneration characteristic of Parkinson's and Alzheimer's diseases. While this mechanism is supported by preclinical models, biomarker studies, and human observational cohorts, direct causal proof in human trials remains an active area of investigation.

0:47:02supportedmoderateYour Anxiety Is a Metabolic Problem, Not a Mental One | Dr.

The functional integrity of the blood-brain barrier declines as humans age.

"Which declines in its functionality as we age and then influence the polarization of the brain's immune system" (said at 0:47:02)

The claim is supported. Neuroimaging studies utilizing dynamic contrast-enhanced MRI (DCE-MRI) and cerebrospinal fluid biomarker analyses (such as soluble PDGFRβ and albumin quotient) have demonstrated that the integrity of the blood-brain barrier undergoes age-dependent breakdown in humans, beginning early in regions such as the hippocampus.

0:00:34supportedmoderateThe Dangers of Fructose & Uric Acid - with Dr. Richard Johns

The human body manufactures fructose via the polyol pathway, which is activated by hypoxia, elevated sodium, dehydration, and high glucose.

"We actually make fructose in the body through activation of what is called the polyol pathway that can be activated by hypoxia, by elevated sodium, by being dehydrated, by having high glucose." (said at 0:00:34)

The speaker's statement is accurate. Endogenous fructose is produced through the polyol pathway (in which aldose reductase converts glucose to sorbitol, and sorbitol dehydrogenase converts sorbitol to fructose). Aldose reductase is activated under conditions of high glucose, osmotic stress (such as high sodium or dehydration), and tissue hypoxia/ischemia as a conserved metabolic and osmoregulatory response.

0:02:08supportedmoderateThe Dangers of Fructose & Uric Acid - with Dr. Richard Johns

A study showed a 70-fold increase in mitochondria in white blood cells in people placed on a low-sodium, low-fructose diet.

"the study I pulled last night about how you demonstrated in white blood cells an incredible 70-fold increase in mitochondria in people going on a low-sodium, low-fructose diet." (said at 0:02:08)

A 2013 randomized trial led by Richard J. Johnson evaluated the effect of dietary fructose and sodium restriction over 8 weeks in 36 overweight and prehypertensive subjects. In the group placed on the low-sodium, low-fructose diet, leukocyte mitochondrial DNA (mtDNA) relative copy number increased from 1.9 at baseline to 147.2 at week 8, representing an approximate 77-fold increase.

0:07:17supportedlowThe Dangers of Fructose & Uric Acid - with Dr. Richard Johns

A June 2016 study in Scientific Reports examining 18 postmortem brains (9 with and 9 without Alzheimer's) found that fructose and sorbitol were increased four- to six-fold in Alzheimer's brains compared to controls.

"You had one literature citation in the book that was from, I think, June of 2016, Scientific Reports, where researchers demonstrated—I think there's a handful, 18 postmortem, nine with and nine without Alzheimer's—that the level of fructose and its immediate precursor from glucose, sorbitol, are increased four- to six-fold in the Alzheimer's brain in comparison to the non-Alzheimer's-afflicted brain." (said at 0:07:17)

The host accurately cites a June 2016 study published in Scientific Reports (Xu et al., PMID 27276998). The researchers analyzed postmortem brain tissue from 9 Alzheimer's disease patients and 9 age-matched controls (18 total) across seven brain regions and found significant elevations in glucose, sorbitol, and fructose throughout the Alzheimer's brains. Because this is a small postmortem observational study (n=18), the GRADE certainty for the underlying physiological phenomenon is low.

0:08:25supportedhighThe Dangers of Fructose & Uric Acid - with Dr. Richard Johns

Fluorodeoxyglucose (FDG) brain imaging studies show that cerebral glucose utilization is compromised in signature Alzheimer's regions long before cognitive symptoms appear.

"I often quote an interesting study that looks at being predictive by doing these FDG, these fluorodeoxyglucose, studies that show brain glucose utilization being compromised in these Alzheimer's signature regions long before people are having these cognitive manifestations." (said at 0:08:25)

Extensive neuroimaging literature and large prospective cohort studies (e.g., ADNI and the Harvard Aging Brain Study) establish that fluorodeoxyglucose (FDG) PET detects reduced cerebral glucose metabolism in signature Alzheimer's disease regions (such as the posterior cingulate, temporoparietal cortex, and entorhinal cortex) in preclinical, cognitively unimpaired individuals, and that baseline hypometabolism is predictive of subsequent cognitive decline and conversion to dementia.

0:15:32needs contextlowThe Dangers of Fructose & Uric Acid - with Dr. Richard Johns

A 2018 study following 1,600 Japanese participants for 12 years found that individuals in the highest uric acid group had an 80% increased risk of all-cause dementia, a 55% increased risk of Alzheimer's, and a 166% increased risk of mixed/vascular dementia.

"there was an interesting study that was in, I think, 2018 of 1,600 Japanese that were followed for 12 years. They had neurocognitive exams every two years and many times they had MRI scans, and they found that dementia in general risk in the highest group of uric acid was increased 80%, and Alzheimer's per se increased 55%, and mixed dementia/vascular was increased 166% in those with the highest uric acid." (said at 0:15:32)

The speaker accurately describes the findings of a 2018 prospective cohort study (Latourte et al., PMID 28754803) involving 1,598 older adults followed over 12 years with brain MRI and cognitive assessments. The study found that individuals in the highest quartile of serum uric acid had an adjusted hazard ratio (HR) of 1.79 (~80% increased risk) for all-cause dementia, an HR of 1.55 (55% increased risk, though not statistically significant, p=0.10) for Alzheimer's disease, and an HR of 3.66 (a 266% increase, which the speaker stated as 166%) for vascular or mixed dementia. However, the study was conducted in Dijon, France (the Three-City Dijon cohort), not in Japan.

0:18:33supportedmoderateThe Dangers of Fructose & Uric Acid - with Dr. Richard Johns

Approximately two-thirds of the purines that produce uric acid in the human body are derived endogenously from tissue recycling rather than from dietary sources.

"recognizing then that we talk about purines being an inroad to raising uric acid as well, but really two-thirds of those purines are not dietary, they're endogenous from recycling of tissue." (said at 0:18:33)

The host's statement accurately reflects standard purine biochemistry and urate physiology: the majority (roughly two-thirds or more) of the purines contributing to uric acid production in humans are generated endogenously through cellular breakdown and turnover of nucleic acids, whereas dietary intake accounts for the remaining minority (approximately one-third).

0:18:55supportedhighThe Dangers of Fructose & Uric Acid - with Dr. Richard Johns

A study published in JAMA evaluating inosine to raise uric acid in Parkinson's disease patients showed that inosine was ineffective at improving scores on the UPDRS rating scale.

"Now we see, I guess about six months ago in JAMA, that a study came out doing that in fact—giving inosine, raising uric acid levels, and then evaluating Parkinson's patients on what's called the Unified Parkinson's Disease Rating Scale, UPDRS, and actually found it was ineffective." (said at 0:18:55)

The speaker accurately describes the SURE-PD3 phase 3 randomized clinical trial published in JAMA (2021). The trial randomized 298 patients with early Parkinson's disease to receive either inosine (to elevate serum urate concentrations) or placebo. The primary outcome was the rate of change in the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) total score. Although inosine successfully raised serum urate levels, the study was halted early for futility because there was no significant difference in MDS-UPDRS progression rates between the inosine and placebo groups.

0:29:40supportedvery lowThe Dangers of Fructose & Uric Acid - with Dr. Richard Johns

In animal models, blocking fructose metabolism prevents the development of alcohol-induced fatty liver disease despite alcohol exposure.

"in the laboratory animal that would crave alcohol, metabolize alcohol, ultimately develop alcoholic fatty liver disease, that by blocking the metabolism of fructose, though they were exposed to alcohol, they would not get alcohol-related fatty liver disease" (said at 0:29:40)

The host's statement accurately reflects findings from mouse research investigating ketohexokinase (KHK, the central enzyme in fructose metabolism). In mouse models, alcohol intake stimulates endogenous fructose production, and both global and liver-specific KHK knockout mice were protected from alcohol-associated liver disease, demonstrating marked reductions in hepatic steatosis (fatty liver), inflammation, and fibrosis even under pair-matched alcohol exposure conditions. Because the available evidence consists entirely of preclinical animal studies, the GRADE certainty is very low.

0:48:20supportedlowThe Dangers of Fructose & Uric Acid - with Dr. Richard Johns

SARS-CoV-2 replicates more efficiently in a glycolytic environment.

"I reviewed a study last night that made it very clear that SARS-CoV-2 virus replicates much more efficiently in a glycolytic environment." (said at 0:48:20)

In vitro and cellular metabolic studies demonstrate that SARS-CoV-2 infection induces metabolic reprogramming toward aerobic glycolysis, and elevated glucose or a glycolytic cellular environment directly facilitates and accelerates viral replication. Studies in human monocytes and lung epithelial cells show that inhibiting glycolysis (e.g., via 2-deoxy-D-glucose) markedly reduces viral replication, while increasing glycolytic flux enhances viral yield. Because the evidence is based on in vitro and ex vivo cellular experiments, the GRADE certainty is rated as low.

0:48:43supportedlowThe Dangers of Fructose & Uric Acid - with Dr. Richard Johns

Hospitalized COVID-19 patients with elevated baseline uric acid have a twofold to threefold increased risk of ICU admission, mechanical ventilation, or death.

"And when we look at that juxtaposed upon the studies that are demonstrating that risk for bad outcome, be it ventilator, ICU, or death, is certainly at least twofold increased, if not threefold, or the composite score having all three is threefold increased in people who enter the hospital with a high uric acid level" (said at 0:48:43)

A retrospective cohort study of 1,854 hospitalized COVID-19 patients (PMID 34025575) evaluated admission serum uric acid levels and adverse outcomes. Patients with elevated baseline serum uric acid (≥423 µmol/L) had a 2.60-fold increased risk of the composite outcome (ICU admission, mechanical ventilation, or death; OR 2.60, 95% CI 1.07-6.29) and a 3.01-fold increased risk of mechanical ventilation (OR 3.01, 95% CI 1.06-8.51). The study also noted a U-shaped relationship, where low serum uric acid levels were also associated with approximately twofold increased risk. Certainty is low due to the observational, retrospective design.

0:58:34supportedmoderateThe Dangers of Fructose & Uric Acid - with Dr. Richard Johns

Elevated uric acid causes hypertension by inhibiting endothelial nitric oxide production.

"the metabolism to uric acid, uric acid's inhibition of nitric oxide leading to hypertension. You mentioned before low-grade inflammation within the kidney" (said at 0:58:34)

Extensive mechanistic and experimental evidence demonstrates that elevated uric acid directly impairs endothelial nitric oxide (NO) bioavailability and endothelial nitric oxide synthase (eNOS) phosphorylation, which leads to endothelial dysfunction, increased vascular resistance, and hypertension.

1:02:31supportedmoderateThe Dangers of Fructose & Uric Acid - with Dr. Richard Johns

Activation of the polyol pathway by glucose, along with elevated sodium and hypoxia, contributes to acquired mitochondrial dysfunction.

"the glucose through activation of the polyol pathway, elevated sodium, hypoxia, big belly, all that stuff feeding into ultimately this acquired mitochondropathy as being a, you know, the bioenergetic explanation" (said at 1:02:31)

Activation of the polyol pathway (aldose reductase pathway) by excess glucose shunts glucose into sorbitol and fructose, depleting NADPH and NAD+, generating reactive oxygen species, and directly impairing mitochondrial bioenergetics and dynamics. Reviews of diabetic and metabolic pathophysiology confirm that polyol pathway activation, alongside hypoxia and related metabolic stressors, drives acquired mitochondrial dysfunction and bioenergetic failure.

1:05:04supportedhighThe Dangers of Fructose & Uric Acid - with Dr. Richard Johns

Uric acid is a downstream metabolite of fructose.

"fructose and its downstream metabolite, uric acid, that tends to amplify all this now-negative aspects of this metabolism, which were once actually survival mechanisms." (said at 1:05:04)

The biochemical pathway linking fructose catabolism to uric acid generation is well established in both animal and human studies. In the liver, fructose is rapidly phosphorylated by ketohexokinase (fructokinase C) without negative feedback, which depletes intracellular ATP and increases AMP. AMP is then converted by AMP deaminase and downstream purine degradation pathways into uric acid.

Fact-checked episodes

Publications